Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P)

被引：0
|
作者：
Birrer, Michael J.
Bondarenko, Igor
Tjulandin, Sergei
Vergote, Ignace
Cibula, David
Ray-Coquard, Isabelle
Colombo, Nicoletta
Allard, Aurore
Oprea, Corina
Rey, Augustin A.
Sessa, Cristiana
Pujade-Lauraine, Eric
机构：
[1] Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA
[2] Dnipropetrovsk Med Acad, Dnepropetrovsk, Ukraine
[3] NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[4] Katholieke Univ Leuven Hosp, Louvain, Belgium
[5] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[6] Ctr Leon Berard, F-69373 Lyon, France
[7] Ist Europeo Oncol, Milan, Italy
[8] Sanofi, Chilly Mazarin, France
[9] Sanofi, Vitry Sur Seine, France
[10] Ist Oncol Svizzera Italiana, Bellinzona, Switzerland
[11] Hop Hotel Dieu, F-75181 Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5516
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study)
    Fujiwara, Hiroyuki
    Ushijima, Kimio
    Nagao, Shoji
    Takei, Yuji
    Shimada, Muneaki
    Takano, Masashi
    Yoshino, Kiyoshi
    Kawano, Yoshiaki
    Hirashima, Yasuyuki
    Nagase, Satoru
    Nishio, Shin
    Nishikawa, Tadaaki
    Ito, Kimihiko
    Shoji, Tadahiro
    Kimura, Eizo
    Takano, Tadao
    Sugiyaman, Toru
    Kigawa, Junzo
    Fujiwara, Keiichi
    Suzuki, Mitsuaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (10) : 1284 - 1291
  • [22] RANDOMIZED PHASE II STUDY OF PACLITAXEL-CARBOPLATIN (PC) VERSUS GEMCITABINE-CARBOPLATIN (GC) FOLLOWED BY PACLITAXEL-CARBOPLATIN (PC) IN PLATINUM-SENSITIVE RECURRENT OVARIAN CARCINOMA (PSROC): A GEICO (SPANISH GROUP FOR INVESTIGATION IN OVARIAN CANCER) STUDY
    Martin, A. Gonzalez
    Casado, A.
    Arranz, J.
    Rubio, M. J.
    Calvo, E.
    Beltran, M.
    Mendiola, C.
    Sanchez, A.
    Santaballa, A.
    Cervantes, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 307 - 307
  • [23] Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
    Meteran, Hanieh
    Knudsen, Anja Or
    Jorgensen, Trine Lembrecht
    Nielsen, Dorte
    Herrstedt, Jorn
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [24] Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma:: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study
    González-Martín, AJ
    Calvo, E
    Bover, I
    Rubio, MJ
    Arcusa, A
    Casado, A
    Ojeda, B
    Balañá, C
    Martínez, E
    Herrero, A
    Pardo, B
    Adrover, E
    Rifá, J
    Godes, MJ
    Moyano, A
    Cervantes, A
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 749 - 755
  • [25] A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC).
    Matei, D.
    Shen, C.
    Fang, F.
    Schilder, J.
    Li, M.
    Arnold, A.
    Zeng, Y.
    Pilrose, J. M.
    Kulesavage, C.
    Balch, C.
    Berry, W.
    Wulfridge, P.
    Huang, T. H.
    Nephew, K. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] Phase 1b of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with carboplatin (C) and paclitaxel (P) in recurrent platinum-sensitive ovarian cancer (OC).
    O'Cearbhaill, Roisin Eilish
    McMeekin, D. Scott
    Mantia-Smaldone, Gina
    Gunderson, Camille
    Sabbatini, Paul
    Cattaruzza, Fiore
    Fischer, Marcus
    Kapoun, Ann M.
    Xu, Lu
    Dupont, Jakob
    Brachmann, Rainer Karl
    Farooki, Azeez
    Moore, Kathleen N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma
    Selle, F.
    Sevin, E.
    Ray-Coquard, I.
    Mari, V.
    Berton-Rigaud, D.
    Favier, L.
    Fabbro, M.
    Lesoin, A.
    Lortholary, A.
    Pujade-Lauraine, E.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2191 - 2196
  • [28] Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-sensitive recurrent ovarian cancer
    Loverix, L.
    Vanderstichele, A.
    Olbrecht, S.
    Van Niewenhuysen, E.
    Van Gorp, T.
    Han, S. N.
    Salihi, R.
    Concin, N.
    Neven, P.
    Busschaert, P.
    Lambrechts, D.
    Vergote, I.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 17 - 18
  • [29] PHASE 2, RANDOMIZED CONTROLLED STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CARBOPLATIN VERSUS GEMCITABINE AND CARBOPLATIN IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (GOTIC003/INTERGROUP STUDY)
    Fujiwara, H.
    Ushijima, K.
    Nagao, S.
    Takei, Y.
    Shimada, M.
    Takano, M.
    Yoshino, K.
    Kawano, Y.
    Hirashima, Y.
    Nagase, S.
    Nishio, S.
    Nishikawa, T.
    Ito, K.
    Shoji, T.
    Kimura, E.
    Takano, T.
    Sugiyama, T.
    Kigawa, J.
    Fujiwara, K.
    Suzuki, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1493 - 1493
  • [30] PHASE 2, RANDOMIZED CONTROLLED STUDY OF PEGYLATED LIPOSOMAL DOXORUBICIN AND CARBOPLATIN VERSUS GEMCITABINE AND CARBOPLATIN IN PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER (GOTIC003/INTERGROUP STUDY)
    Fujiwara, H.
    Ushijima, K.
    Nagao, S.
    Takei, Y.
    Shimada, M.
    Takano, M.
    Yoshino, K.
    Kawano, Y.
    Hirashima, Y.
    Nagase, S.
    Nishio, S.
    Nishikawa, T.
    Ito, K.
    Shoji, T.
    Kimura, E.
    Takano, T.
    Sugiyama, T.
    Kigawa, J.
    Fujiwara, K.
    Suzuki, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 286 - 286
12345